Design and development of a mobile chemotherapy drug guide (ChemoNurse) for oncology nurses: a feasibility and usability pilot study Authors: Remziye Semerci Şahin, Lara Gül Küçükdevlet, Betül Korkmaz, Mustafa Emir İlhan, Arda Burak Yeni, Zindan Kurt, Aslı Akdeniz Kudubeş, Fatma Gündoğdu, Arzu Tuna, Esra Tayaz, Esra İbek, Enes Şimşek, Pınar Yılmaz, İrem Yıldız Çilengiroğlu, Fatih Selcukbiricik, Beren Semiz, Emre Gürsoy Published: 2026 ABSTRACT AbstractObjectiveThis study aims to design, develop, and evaluate the feasibility of a mobile chemotherapy drug guide (ChemoNurse) tailored for oncology nurses. The evaluation focused on feasibility, usability, and acceptability outcomes. ChemoNurse includes drug preparation, storage methods, administration routes, administration duration, dosage calculation, side effects, patient education, and symptom management.MethodsThis feasibility study was conducted between August 1, 2023, and August 1, 2024, with 34 oncology nurses from the Turkish Oncology Nursing Society. The Standard Protocol Items: Recommendations for Interventional Trials checklist was utilized. The RE-AIM framework was used to guide the evaluation of early implementation outcomes, particularly feasibility, usability, and acceptability. The evaluation framework integrates usability, perceived usefulness, acceptability, and feasibility. The Information Form, ChemoNurse Evaluation Form, Mobile Application Usability Scale, Satisfaction Scale, and semi-structured interview form were used for data collection.ResultsThe nurses’ mean age was 32.79 ± 6.55 years, 91.2% female, and most had over ten years of professional experience. The evaluation of ChemoNurse’s usability demonstrated high acceptance and perceived usefulness among oncology nurses. 94.1% of participants rated the application as easy to use, and 100% of participants reported that the content was understandable and clinically relevant. Additionally, 85.3% of participants considered the drug guide content clinically sufficient, and 91.2% confirmed that the application met their clinical needs. The application was perceived as cost-effective by all participants, and 97.1% of participants indicated they would continue using ChemoNurse in clinical practice. The Mobile Application Usability Scale results further supported these findings, with 91.2% of nurses scoring above 200 and a mean usability score of 246.76 ± 38.13.ConclusionsPreliminary evidence suggests that ChemoNurse is usable and acceptable for supporting oncology nurses’ point-of-care access to chemotherapy information within this pilot sample; larger studies are needed to confirm its clinical impact. ChemoNurse demonstrated promising feasibility, usability, and acceptability within this pilot sample. Future studies with objective outcome measures are needed to evaluate its potential perceived usefulness and implementation feasibility in clinical practice.Keywords: Mobile, Chemotherapy, Nursing, Feasibility studies, Drug guide Introduction The escalating global and national burden of cancer, with millions of new diagnoses annually, necessitates comprehensive and dynamic care strategies [1, 2]. Within this complex landscape, chemotherapy remains a cornerstone of oncological treatment [3]. While chemotherapy agents are effective at inhibiting the proliferation of cancer cells, their non-selective nature also affects rapidly dividing healthy cells, leading to serious side effects such as infections, bleeding, and organ toxicity [4]. Oncology nurses, as highly specialized and knowledgeable healthcare providers, must possess advanced expertise in chemotherapy agents to ensure safe drug administration, early recognition of adverse effects, and appropriate management [5, 6]. The safe administration of chemotherapy requires rigorous adherence to complex protocols, precise dosage calculations, and vigilant monitoring for toxicity. In the Turkish clinical context, high patient volumes and heavy workloads make real-time dose verification and prompt toxicity monitoring the most significant and error-prone challenges in daily practice [7, 8]. However, oncology nurses frequently face educational deficiencies regarding rapidly evolving chemotherapy regimens, compounded by high clinical workloads and limited access to standardized point-of-care resources [5, 9]. Consequently, addressing these educational gaps through mHealth-based continuing professional development (CPD) has emerged as a critical global priority [10]. Digital decision-support tools and mobile educational applications hold considerable perceived potential to support oncology nursing practice by facilitating access to structured clinical information, reinforcing knowledge, and bridging the gap between theoretical knowledge and dynamic clinical practice, though the evidence base for objective improvements in error rates and clinical competency remains limited [11–13]. Widely adopted global clinical decision-support systems and pharmacological databases provide comprehensive, evidence-based medical information. However, their applicability and adoption within the daily clinical workflows of oncology nurses in non-English-speaking or resource-constrained settings, such as Türkiye, remain significantly limited [10, 11]. These platforms are predominantly physician-oriented, focusing heavily on diagnostics and medical management rather than the highly specific, step-by-step nursing interventions required for safe preparation, administration, and real-time toxicity monitoring of chemotherapy drugs [11]. Furthermore, significant structural barriers, namely language constraints and prohibitive institutional subscription costs, severely restrict point-of-care accessibility for bedside nurses [11]. Consequently, there is a critical need for accessible, localized, and strictly nurse-centric mobile health (mHealth) interventions to bridge this specific clinical gap [10]. The complexity and variability of chemotherapy, ranging from drug mechanisms and dosages to cancer-specific indications and infusion times, demand a high level of clinical competence from oncology nurses [14]. Moreover, optimizing patient care, therapeutic outcomes, and quality of life requires the individualized management of physical and psychological symptoms as well as the prevention of treatment-related complications [15]. In Türkiye, the absence of formal, mandatory certification programs for the safe handling of antineoplastic drugs creates a significant educational gap for bedside nurses [8]. Consequently, oncology nurses frequently enter the clinical setting relying on intermittent in-service training and report a strong need for structured, up-to-date education to manage the complexities of safe chemotherapy administration and occupational safety protocols [7, 8]. In response to these challenges, professional organizations and national health authorities have emphasized the need for comprehensive nursing education and have defined clear responsibilities for chemotherapy practice in oncology nursing [16]. However, the dynamic nature of cancer care and the demanding workloads in clinical settings hinder nurses’ ability to stay abreast of evolving knowledge and protocols [17]. Consequently, there is a growing need for innovative, accessible tools that provide reliable, evidence-based information at the point of care [9]. Recent systematic reviews highlight that mHealth technologies have emerged as crucial tools in clinical practice, demonstrating significant potential to alleviate pressure on healthcare systems, enhance the overall quality of care, and support the continuous education and clinical competency of nursing professionals [10]. By delivering up-to-date knowledge within nursing workflows, mHealth solutions support both improved patient outcomes and more effective nursing practice. With the widespread use of smartphones, even in resource-limited settings, mobile applications offer a promising platform for real-time access to information and professional support [18, 19]. However, in oncology, mobile applications specifically designed for nurses, particularly those focusing on chemotherapy drug management, remain insufficient [10, 20]. This study addresses this critical gap by developing ChemoNurse, a mobile chemotherapy drug guide specifically designed for oncology nurses. While ChemoNurse encompasses multiple functions, its primary conceptual mechanism targets nurses’ clinical decision-making at the point of care, specifically through real-time dose verification and toxicity monitoring, with standardized patient education serving as a secondary, supportive function. Developed through collaboration with clinical experts and grounded in current literature and regulatory standards, the tool aims to support nurses in accessing structured, evidence-based information at the point of care. Whether ChemoNurse contributes to enhanced symptom control, improved treatment adherence, or patient safety outcomes remains to be established in future perceived usefulness studies. Method Study purpose This study aims to design, develop, and evaluate the feasibility of a mobile chemotherapy drug guide (ChemoNurse) tailored for oncology nurses. ChemoNurse includes drug preparation, storage methods, administration routes, administration duration, dosage calculation, side effects, patient education, and symptom management. Study design The primary aim of this study was to develop and evaluate the early-phase feasibility of ChemoNurse, operationalized through three core outcomes: usability, acceptability, and preliminary implementation indicators aligned with the RE-AIM framework. Usability testing and pilot feedback are subcomponents of this overarching feasibility aim and do not constitute independent study objectives. This study adheres to the following reporting standards: the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist for feasibility trial reporting; the Template for Intervention Description and Replication (TIDieR) checklist for intervention description; and the mHealth Evidence Reporting and Assessment (mERA) checklist for mHealth-specific reporting. This feasibility study was conducted between August 1, 2023, and August 1, 2024, with 34 oncology nurses from the Turkish Oncology Nursing Society. The Standard Protocol Items: Recommendations for Interventional Trials checklist was utilized. The RE-AIM framework was used to guide the evaluation of early implementation outcomes, particularly feasibility, usability, and acceptability. The evaluation framework integrates usability, perceived usefulness, acceptability, and feasibility. The study was conducted in three sequential phases. In Phase 1 (Development and Expert Review), the application content was developed and reviewed by a multidisciplinary expert panel prior to any nurse involvement. In Phase 2 (Iterative Pilot Feedback), a small subset of oncology nurses tested early versions of the application and provided informal feedback that informed content and interface refinements; these informal responses were used solely for development purposes and do not constitute the study dataset. In Phase 3 (Formal Feasibility Evaluation), 34 oncology nurses used the finalized version of ChemoNurse for one week and completed the ChemoNurse Evaluation Form, Mobile Application Usability Scale, Satisfaction Scale, and semi-structured interview. All quantitative and qualitative data reported in the Results section were derived exclusively from this Phase 3 evaluation. This study was designed as a feasibility study to evaluate initial user experiences from short-term use of the application. In early-phase evaluation studies of digital health applications, short-term usage periods (1–2 weeks) have been reported to be sufficient for determining users’ initial interactions, perceptions of usability, and levels of acceptability [21, 22]. Accordingly, a one-week usage period was deemed appropriate for evaluating the app’s usability, acceptability, and initial user interactions. However, this duration is insufficient for assessing long-term usage patterns, habit formation, or full integration into clinical workflows. Indeed, it has been emphasized that longer follow-up periods are needed to assess sustainable use and behavioral adaptation in digital health interventions [23]. Study participant This study was conducted with the participation of oncology nurses working at various institutions across Turkey and is not a single-center study. The participants consist of nurses working in different hospitals and clinical settings (university hospitals, teaching and research hospitals, and other healthcare institutions). Participants were recruited for the study through the Turkish Oncology Nursing Association using an appropriate sampling method. Invitations to participate were sent via email groups and online professional communication channels. Nurses who met the inclusion criteria and wished to participate were enrolled in the study on a voluntary basis. Of the nurses who received the invitation and met the inclusion criteria, 34 agreed to participate. Given the voluntary and self-selected nature of recruitment through a single professional society, the sample may over-represent nurses with higher professional engagement and digital literacy relative to the broader oncology nursing workforce; this is acknowledged as a limitation of the study. No financial or non-financial incentives were provided to participants. Participant selection was based directly on individual participation, and no referrals were made through nurse managers or institutional administrators. The study’s inclusion and exclusion criteria were applied, and participants who met them were included in the sample. In line with methodological recommendations, the sample size for the feasibility study was determined by the approach of conducting pilot studies with groups of 20–30 individuals who share characteristics with the target population. Accordingly, the study was conducted with 34 oncology nurses, 17 of whom work in pediatric oncology units and 17 in adult oncology units. Inclusion and exclusion criteria The inclusion criteria for the study were as follows: nurses who actively administer chemotherapy, possess basic smartphone competency (e.g., the ability to download and navigate Android or iOS mobile applications), have at least 1 year of experience working in oncology clinics, and are willing to participate voluntarily. Exclusion criteria included nurses who had not completed the oncology clinic orientation process, those who had never administered chemotherapy, participants who provided incomplete responses to the data collection form, and those who wished to withdraw from the study at any stage. Data collection tool The evaluation framework integrates usability, perceived usefulness, and feasibility. The Information Form, ChemoNurse Evaluation Form, Mobile Application Usability Scale, Satisfaction Scale, and semi-structured interview form were used to collect data. The ChemoNurse Evaluation Form is one of the assessment tools developed by researchers to evaluate the feasibility of the ChemoNurse mobile application. The ChemoNurse Evaluation Form was developed by the research team through a structured process informed by a comprehensive review of the relevant literature on mobile health application evaluation, chemotherapy nursing practice, and digital tool usability assessment. The initial item pool was generated based on the core evaluation dimensions identified in the literature, including usability, content adequacy, clinical relevance, comprehensibility, accessibility, and user satisfaction. After the initial version was developed, the form was submitted to a multidisciplinary expert panel for content validation. The panel consisted of nine specialists, including pediatric and adult oncology nurses with advanced clinical experience, a medical oncologist, a clinical pharmacist, and a nursing education specialist. Experts were asked to evaluate each item on clarity, clinical relevance, and comprehensiveness using a structured review form. Items were assessed on a four-point content validity scale (1 = not relevant, 2 = somewhat relevant, 3 = relevant, 4 = highly relevant), and the Content Validity Index (CVI) was calculated for each item. Items with an item-level CVI (I-CVI) below 0.78 were either revised or removed based on expert feedback. Item-level CVIs for the seven retained items ranged from 0.78 to 1.00 (Ease of use: I-CVI = 1.00; Understandability: I-CVI = 0.89; Clinical suitability: I-CVI = 0.89; Drug guide adequacy: I-CVI = 0.78; Clinical need alignment: I-CVI = 1.00; Cost-effectiveness: I-CVI = 0.89; Intention for continued use: I-CVI = 1.00); all items met or exceeded the 0.78 threshold for content validity. Following two rounds of expert review, the final form achieved a scale-level CVI (S-CVI) of 0.92, indicating strong content validity. The revised form was subsequently piloted with five oncology nurses who were not included in the main study sample to assess clarity and face validity. Minor wording adjustments were made based on this feedback before the form was finalized. The final ChemoNurse Evaluation Form included items on ease of use, understandability of content, sufficiency of drug guide content, alignment with clinical needs, cost-effectiveness, and intention for continued use, along with open-ended items to capture qualitative feedback. All items were reviewed and approved by the full research team prior to implementation. A full description of the instrument development and validation process, including expert panel composition, CVI calculations, and pilot testing procedures, is provided in this section to ensure transparency and support the interpretability of findings based on this tool. Mobile Application Usability Scale The Mobile Application Usability Scale was originally developed by Hoehle and later adapted into Turkish by Güler in 2019 [24]. This measurement tool evaluates features of mobile applications, including color schemes, typography, font sizes, navigation, and overall manageability. In her study, Güler adapted the scale into Turkish and tested its nomological network within a structural measurement model [24]. Based on the Technology Acceptance Model, the scale examines the relationship between perceived usability, intention to continue using the application, brand loyalty, and actual use of mobile applications. The model incorporates these four variables and was tested with data collected from 476 participants. To assess the validity and reliability of the scale, translation procedures, confirmatory factor analysis (CFA), and reliability tests were conducted. CFA results confirmed that the original structure of the three subscales was preserved in the Turkish version. The Cronbach’s alpha coefficients for all constructs were within acceptable ranges. Specifically, the reliability coefficients (Cronbach’s alphas) for all Mobile Application Usability Scale factors were high, ranging from 0.74 to 0.94. In the current study sample (n = 34), internal consistency was similarly high: Cronbach’s α = 0.91 for the total scale, α = 0.89 for the Perceived Usability subscale, α = 0.82 for Intention to Continue Use, and α = 0.78 for Brand Loyalty, indicating adequate reliability within this pilot sample. The scale consists of 40 items rated on a 7-point Likert scale: 7 (Strongly Agree), 6 (Agree), 5 (Somewhat Agree), 4 (Neutral), 3 (Somewhat Disagree), 2 (Disagree), and 1 (Strongly Disagree). Scores were computed by summing responses across all 40 items, yielding a total score ranging from 40 to 280. Subscale scores were computed separately for each of the three subscales: Perceived Usability, Intention to Continue Use, and Brand Loyalty. No imputation was applied as there were no missing item responses. No formal outlier exclusion procedure was applied, given the small sample size; the full score distribution is reported to allow independent assessment of floor and ceiling effects. Development of the ChemoNurse mobile application While developing the app’s content, international chemotherapy safety guidelines were used as a basis, and clinical practices in Turkey, as well as the requirements of the current healthcare system, were also taken into account. The ChemoNurse mobile application was developed by the researchers as a guide to support oncology nurses in chemotherapy administration, based on an extensive literature review [25–28]. In Turkey, 58 chemotherapy drugs are used for pediatric and adult cancer patients. Although these drugs share common characteristics, they vary in dosage calculations and administration procedures. The current version of ChemoNurse covers conventional cytotoxic chemotherapy agents exclusively and does not include targeted therapies, immunotherapies, or combination regimens. This scope was defined based on the needs assessment conducted with 45 oncology nurses prior to development, which identified cytotoxic drug preparation, administration safety, and toxicity monitoring as the highest-priority informational needs at the point of care. The application includes 58 cytotoxic agents used in both pediatric and adult oncology practice in Turkey, organized across six pharmacological categories. All content was developed in alignment with international guidelines, including CTCAE v5.0, ASCO/ONS Chemotherapy Administration Safety Standards, and NCCN Clinical Practice Guidelines, and is subject to biannual review by the multidisciplinary expert panel, with an expedited update pathway for urgent safety-relevant changes. In the mobile application, drugs are not organized by treatment protocols but rather by chemotherapy drug categories. The content structure was based on individual drugs, as exemplified by 5-Fluorouracil. Therefore, the mobile application categorizes the drugs as follows: Antineoplastic Agents – Antimetabolites Antineoplastic Agents – Antimetabolites Antineoplastic Agents – Alkylating Agents Antineoplastic Agents – Alkylating Agents Antineoplastic Agents – Plant-Derived Antineoplastic Agents Antineoplastic Agents – Plant-Derived Antineoplastic Agents Antineoplastic Agents – Antibiotics Antineoplastic Agents – Antibiotics Antineoplastic Agents – Hormones and Hormone Antagonists Antineoplastic Agents – Hormones and Hormone Antagonists Antineoplastic Agents – Other Antineoplastic Agents Antineoplastic Agents – Other Antineoplastic Agents Symptom management algorithms were developed based on the most recent evidence in the literature and expert clinical opinions. These algorithms aim to provide best practice guidance for managing specific symptoms and improving patients’ quality of life. Relevant scales or assessment tools accompany each symptom in the symptom management section. The National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, evaluated symptoms across different disease types and age groups. Analysis phase of the ChemoNurse application To identify the necessary content areas of the mobile application, interviews were conducted with 45 adult and pediatric oncology nurses. The discussions focused on determining needs related to chemotherapy drug administration, preparation, storage, cytotoxic waste disposal, symptom management, and patient education. The application’s content scope was shaped by the literature and the researchers’ clinical expertise. The final content of the ChemoNurse application includes the following key sections: Design phase of the ChemoNurse application The application was designed to be informative, supportive, summarizing, and evaluative. The graphical design was developed with professional support to ensure the application would enhance oncology nurses’ knowledge and attitudes toward chemotherapy practices and achieve the desired educational impact across various user profiles. Development phase of the ChemoNurse application ChemoNurse was developed as a cross-platform mobile application compatible with both Android and iOS devices, using a cloud-based infrastructure to ensure real-time data synchronization and accessibility in clinical settings. The technical architecture was designed to support rapid content retrieval and secure access, enabling nurses to use the application efficiently during time-sensitive clinical tasks. Further technical details regarding the system architecture are illustrated in Fig. 1. System architecture The application’s content was structured around the core steps of the Nursing Process assessment, planning, implementation, and evaluation to ensure alignment with established nursing practice standards. Each chemotherapy drug module was organized to reflect the sequential clinical responsibilities of oncology nurses, covering drug preparation, administration routes, dosage calculation, toxicity monitoring, and patient education. Symptom management algorithms were developed based on the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE, v5.0) and current evidence-based oncology nursing guidelines, providing nurses with standardized, graded guidance for recognizing and responding to treatment-related adverse events. Patient safety was a central organizing principle in content development. Drug preparation and administration content was aligned with internationally recognized safe handling standards for antineoplastic agents, with attention to occupational safety and dosage verification. The calculator module incorporated validated formulas for BSA and carboplatin dosing to support accurate dose calculations; whether these features reduce computation errors in practice requires evaluation in future implementation studies. Database preparation and module development The raw medical data were structured into a hierarchical format to enable efficient retrieval and seamless user presentation. The user interface was designed with intuitive navigation, including expandable categories, visual grids, and dynamic search and filter functions, allowing nurses to access specific drug or symptom information instantly. To enhance readability and reduce cognitive load, a color-coded visual hierarchy was implemented, helping users easily differentiate between parent categories and sub-items during busy clinical shifts. The educational content used in this study was developed by the research team based on current evidence-based international oncology nursing guidelines and standard symptom management protocols rather than relying solely on locally generated institutional materials. Although the University School of Nursing supported access to educational infrastructure and implementation processes, the clinical content itself was derived from internationally recognized sources, including established oncology nursing practice standards and supportive care guidelines relevant to symptom management in patients with cancer. To ensure clinical accuracy and consistency, all educational materials were reviewed by expert oncology nursing faculty members and clinicians with experience in symptom management and supportive cancer care. This expert review process helped confirm content validity, appropriateness, and alignment with contemporary oncology nursing practice. Clarifying this process strengthens the methodological rigor of the intervention and supports the credibility and transferability of the findings. The clinical content of ChemoNurse was systematically organized and uploaded to a secure cloud-based database, categorized into four primary modules: Drugs, Symptoms, Toxicities, and Educational Materials. This structured organization enables the application to retrieve and display information rapidly in response to user queries. Content updates are managed centrally, meaning that any revisions to drug information or clinical guidelines can be applied across the application without disrupting the user experience. Each module was designed with nurses’ point-of-care needs in mind. A real-time search function allows nurses to locate specific drugs, symptoms, or toxicities instantly by typing partial names, without needing to browse through the full content. The Drugs and Symptoms modules display entries with accompanying images and pharmacological classifications, and selecting any item opens a detailed information page. The Toxicities module presents symptoms in expandable sections, allowing nurses to view subcategories and detailed descriptions only when needed, reducing visual clutter during time-pressured clinical tasks. The Educational Materials module is organized by major topic areas with clearly ordered subheadings for easy navigation. The application’s visual design was developed to support readability and reduce cognitive load. Content is presented in a layered card format with alternating background shading to help users distinguish between main categories and subcategories at a glance. Color-coded navigation tabs indicate the active section, and a zoom function is available for detailed visual content such as toxicity grading tables. Where data is unavailable, clear placeholder messages are displayed to ensure the interface remains transparent and user-friendly. Authentication and user management Access to ChemoNurse is restricted to verified healthcare professionals through a secure registration and login system. During registration, nurses provide their professional contact details, and email verification is required before an account becomes active. This verification step ensures that the application remains accessible only to qualified clinical users, protecting both data privacy and the integrity of the professional community within the platform. Standard account management functions, including password reset and account deletion, are available to all users. The application also supports personalized push notifications to keep users informed of relevant updates. The forum module was optimized for real-time communication, enabling nurses to share clinical experiences and visual data such as test results or clinical images. To ensure reliable performance even in hospital environments with limited internet connectivity, automatic image optimization and efficient data loading strategies were integrated, minimizing data usage and reducing loading times. Calculator module The calculator module provides nurses with tools to compute chemotherapy dosages and body surface area (BSA), a key parameter in determining individualized chemotherapy doses. Nurses can select from internationally established BSA calculation methods, including the DuBois and Mosteller formulas, and toggle between measurement units based on clinical preference. Carboplatin dosing is also supported within the module. Built-in validation checks and informative error messages guide users through each calculation step, helping to prevent input errors and support accurate, safe determination at the point of care. To further support safe use, each drug information page includes a disclaimer that prompts nurses to verify dosage and administration parameters with the responsible physician or pharmacist before clinical application. Per-drug maximum does threshold alerts are not currently embedded within individual drug entries; this represents a recognized limitation and a priority objective for the next development phase. Forum module A key feature of ChemoNurse is the forum module, which provides a dedicated space for oncology nurses to interact, share clinical knowledge, and discuss complex cases in real time (Fig. 1). Nurses can initiate discussions by creating posts that include both text and images, such as photographs of infusion site reactions, laboratory results, or clinical documentation, either uploaded from their device or captured directly within the application. Other users can read and respond to posts via the comment function, and a peer-voting system allows nurses to upvote or downvote comments based on their clinical relevance and accuracy. The most highly rated comments are displayed at the top of each thread, enabling nurses to quickly identify the most useful and clinically validated responses. The forum was engineered to perform reliably under the connectivity constraints typical of busy hospital environments. Content loads progressively as the user scrolls, reducing initial loading times and minimizing data usage, which is an important consideration for nurses accessing the application on clinical wards. Images are automatically optimized before uploading to further support performance. When posts or comments are deleted, associated images are simultaneously removed to maintain data integrity within the system. The forum’s design reflects a deliberate effort to support not only peer communication but also a broader culture of collaborative professional learning among oncology nurses. By enabling nurses to share real-world clinical experiences, seek collegial input, and access the collective expertise of their professional community, the forum extends the application’s value beyond individual decision support toward a platform for ongoing professional development. These features were considered integral to the overall feasibility and acceptability of ChemoNurse, contributing directly to its relevance and utility in clinical settings. Given that the forum permits image sharing and peer-to-peer clinical discussion among healthcare professionals, appropriate safety governance is a critical design requirement. The following safeguards are incorporated into the current version: (1) forum content is subject to moderation by designated administrator accounts held by members of the research team; posts flagged by the peer-voting system as clinically inaccurate or potentially unsafe are reviewed within 24 hours and removed if confirmed problematic; (2) explicit community guidelines prohibit advice that contradicts evidence-based standards or could encourage unsafe clinical practice, and users are reminded of these guidelines during onboarding and at the point of posting; (3) a mandatory image review step is embedded in the upload workflow, prompting users to confirm that images do not contain patient-identifiable information (including faces, names, hospital identifiers, or unique clinical identifiers visible in laboratory reports or imaging documentation) before any image is published; and (4) images are automatically stripped of EXIF metadata prior to upload to prevent inadvertent disclosure of device or location data. A formal moderation protocol with documented escalation procedures, and a clearer policy on the scope and limitations of peer advice provided via the forum, are acknowledged as development priorities for subsequent versions and should be in place before any wider deployment of this feature. ChemoNurse operates through two interconnected components: a user-facing interface and a secure cloud-based backend (Fig. 1). The interface provides nurses with access to six clinical modules: Drugs, Symptoms, Toxicities, Calculator, Forum, and Educational Materials through a clean, consistent design optimized for use across both Android and iOS devices. The backend manages two distinct types of data: structured clinical content, including drug information, symptom algorithms, toxicity criteria, and educational materials, which is stored and retrieved in real time in response to user queries; and user-generated data, including forum posts, comments, votes, and notification preferences, which is synchronised instantly across all users so that new contributions are visible to the entire community without delay. User access is controlled by a secure authentication layer that restricts participation to verified healthcare professionals, ensuring that sensitive functions, such as the forum and clinical calculators, remain within a trusted professional environment. This architecture was selected to ensure scalability, data security, and reliable real-time performance, all critical requirements for a clinical support tool intended for use in busy oncology settings. ChemoNurse was developed as a cross-platform application compatible with Android and iOS devices, using a cloud-based infrastructure that ensures real-time content synchronization, allowing updates to guidelines and drug information to be immediately available to all users without manual app updates. Testing Each module was tested independently. The drugs, symptoms, and toxicity modules achieved average data retrieval speeds of under 200 ms. The calculation module has produced consistent results when compared to ONCOassist comparison data. Forum features such as posting, searching, voting, and commenting were extensively tested, and performance optimizations, such as image compression, improved load times. Feedback from professionals confirmed the system’s usability and functional completeness. Multidisciplinary Expert Panel: Prior to the official release of ChemoNurse to nurse users, all clinical content underwent a structured validation process to ensure accuracy, completeness, and alignment with current chemotherapy safety standards. To ensure clinical accuracy and safety, a multidisciplinary expert panel was convened, comprising pediatric and adult oncology nurses, a medical oncologist, a clinical pharmacist, and a nursing education specialist from Koç University Hospital, Hospital, and Hacettepe University Oncology Hospital. The panel reviewed all application modules against current clinical guidelines and provided structured feedback on three specific dimensions: (1) the accuracy and completeness of drug information relevant to safe chemotherapy administration; (2) the clinical appropriateness of symptom management algorithms and toxicity grading criteria; and (3) the clarity and usability of patient education content within real-world nursing workflows. Based on expert input, decision-support content was refined to ensure that the guidance embedded in each module was actionable, evidence-based, and aligned with the clinical reasoning nurses employ during chemotherapy administration. The panel reviewed all drug information modules against three specific safety dimensions: (1) pharmacological accuracy and completeness of drug preparation, dosage, and administration information; (2) clinical appropriateness of toxicity grading and symptom management algorithms relative to CTCAE v5.0 and NCCN guidelines; and (3) alignment of safe handling content with ASCO/ONS Chemotherapy Administration Safety Standards. Discrepancies identified during review were resolved through structured consensus discussion, and all content was revised accordingly before the application was made available to participants. Modular Content Structure: The application’s content was organized into six clinically meaningful modules Drugs, Symptoms, Toxicities, Calculator, Forum, and Educational Materials each reflecting a distinct domain of oncology nursing practice. This modular structure allows nurses to navigate directly to the information relevant to their immediate clinical need, minimizing cognitive load during busy shifts. Prior to finalization, dedicated feedback mechanisms were incorporated into the application to collect structured input from nurses regarding content clarity, clinical relevance, and ease of use. This feedback informed iterative revisions throughout the development process and contributed to the high usability and acceptability observed in the pilot evaluation. Given the rapidly evolving nature of chemotherapy protocols, dosing guidelines, and supportive care standards, a structured content update mechanism has been established for ChemoNurse to ensure long-term clinical accuracy and data integrity. Content within the application is reviewed biannually by the multidisciplinary expert panel, which includes oncology nurses, a medical oncologist, and a clinical pharmacist. During each review cycle, all drug information, toxicity grading criteria, and symptom management algorithms are cross-referenced against the most current versions of internationally recognized guidelines, including CTCAE v5.0, ASCO/ONS Chemotherapy Administration Safety Standards, and NCCN Clinical Practice Guidelines. Any identified discrepancies or newly approved drugs are flagged for revision before re-uploading to the Firebase Realtime Database. In addition to scheduled reviews, an expedited update protocol has been defined for urgent safety-relevant changes, such as newly identified drug interactions or guideline revisions affecting dosing, which are reviewed and implemented within two weeks of identification. All content revisions are documented with version numbers and update dates, which are visible to users in the application, allowing clinicians to verify the currency of the information they access. User Testing and Feedback: Dedicated sections within the mobile application were designed to collect feedback from oncology nurses on usability, content clarity, and functional features. This feedback was utilized both before and after the official launch of the application to support its continuous improvement and refinement. Pilot study Following revisions based on expert feedback, a pilot study of the ChemoNurse mobile application was conducted with oncology nurses (Fig. 2). Figure 2 illustrates the sequential workflow for this pilot phase, encompassing expert review, content revision, a one-week nurse evaluation, structured feedback collection, and final application refinement. The literature recommends that applications or measurement tools be tested with a group of 20–30 individuals who possess similar characteristics to the target sample but are not included in the primary study sample [29, 30],In line with this recommendation, the pilot implementation in this study was carried out with 34 oncology nurses (17 pediatric, 17 adult). During this phase, participating nurses provided feedback on the application’s content and design. The mobile application’s content, graphical design, information presentation, and assessment tools were reviewed and revised as needed. Based on the feedback, the ChemoNurse application was updated, and the development process was finalized. Pilot study implementation workflow of the ChemoNurse mobile application Expert opinions were sought after the researchers prepared the initial version of the mobile application. Based on their suggestions, the application was revised and finalized. The usability and appropriateness of the application were simultaneously evaluated by 34 oncology nurses using the Mobile Application Usability Scale. Nurses participating in the evaluation were asked to use the mobile application for 1 week and to provide their opinions on its ease of use, clarity, benefits, and informational content. The application was revised once more based on feedback from both experts and nurses and finalized for official use. Data Analysis The data analysis in this feasibility study was structured to assess three core parameters: feasibility, acceptability, and usability of the ChemoNurse mobile application. Additionally, the Implementation evaluation of the ChemoNurse mobile application was aligned with the RE-AIM framework (Table 1). Table 1RE-AIM framework for data collectionOutcomesData collectedTimingReachInformation FormAt baseline, during participant enrolmentPerceived UsefulnessChemoNurse Evaluation FormAfter one week of application useAdoptionChemoNurse Evaluation FormAt the time of pilot testing with 34 oncology nursesImplementationMobile Application Usability ScalePost-application usage evaluationMaintenanceSemi-structured Interview FormPost-application usage evaluation RE-AIM framework for data collection Feasibility Parameters: Quantitative data on the application’s feasibility were analyzed using descriptive statistics, including measures of frequency, mean, median, and standard deviation. This analysis aimed to evaluate the application’s usability, clarity, accessibility, and content adequacy. Additionally, participant demographics (e.g., age, level of education, clinical area, years of oncology experience) were descriptively analyzed to examine their association with responses to the feasibility tools, including the ChemoNurse Evaluation Form and the Mobile Application Usability Scale. Acceptability Parameters: Qualitative data were collected through open-ended survey responses and semi-structured interviews. A content analysis approach combining inductive and deductive coding was used to identify patterns, themes, and shared perceptions of the ChemoNurse application’s content, structure, and usability. Qualitative data were collected through semi-structured interviews with all 34 participants, each lasting approximately 15–20 minutes, and through open-ended responses on the ChemoNurse Evaluation Form. Interviews were audio-recorded with participant consent and transcribed verbatim. Thematic analysis followed an inductive-deductive approach: two researchers independently coded the transcripts and open-ended responses (one researcher held a doctoral-level background in oncology nursing with qualitative research experience; the second was a doctoral candidate in pediatric nursing with prior training in thematic analysis), after which emerging codes were compared, discrepancies resolved through consensus discussion (no formal inter-rater reliability statistic was calculated; disagreements were resolved by discussion until full consensus was reached, and any persistent disagreement was referred to a third senior researcher for adjudication), and themes refined iteratively. Analytical rigor was supported through independent dual coding, consensus-based theme refinement, and member checking, in which a subset of participants reviewed the preliminary themes for accuracy and resonance. Given the focused scope of the interview questions and the homogeneity of the sample, thematic saturation was considered achieved within the dataset. Final themes were reviewed and approved by the full research team. Semi-structured interview responses were analyzed using inductive thematic analysis; emerging themes were refined through team discussion until consensus was reached, and representative nurse quotes were selected to illustrate each theme (Table 2). Table 2Thematic summary of nurses’ suggestions for improving ChemoNurseThemeSuggestionNurses’ StatementsTheme 1: Drug Preparation and Administration SafetyEnhance subcutaneous drug preparation details“For Vidaza, preparation steps should explain that the drug must not contact the needle tip or skin, as this can cause skin toxicity. Also, patient relatives should be informed clearly about possible redness, pain, and firmness after injection.”Add stability and storage information“Stability and storage conditions should be written for all drugs.”Theme 2: Dosage Accuracy and IndividualizationClarify drug doses by diagnosis and BSA“For each drug, the dose to be given per m2 depending on the disease should be written more clearly.”Add a BSA calculator“There is BMI calculation, but since drugs are dosed by m2, a BSA calculator should also be added.”Include dose adjustment for special conditions“Dose adjustments could be suggested for patients with impaired renal or liver functions.”Theme 3: Clinical Decision Support and Emergency PreparednessInclude oncologic emergencies“You can add oncologic emergencies such as hypersensitivity and allergic reactions.”Group toxicities by protocol“Toxicities can be grouped by chemotherapy protocols to highlight which side effects are more common with each regimen.”Complete side effect sections“Specific major side effects are included, but minor ones are missing. These should be completed or removed.”Theme 4: Content Organization and NavigationCategorize and alphabetize drugs“Drugs can be grouped (e.g., antineoplastics, monoclonal antibodies) and listed in alphabetical order within each group.” Thematic summary of nurses’ suggestions for improving ChemoNurse Perceived Impact: To explore the application’s potential perceived impact on nurses’ knowledge and attitudes, evaluated with the ChemoNurse Evaluation Form. Descriptive statistics were used to examine scores. Although no clinical intervention was applied in this feasibility phase, the outcome patterns provided insight into potential user feedback and the perceived usefulness of ChemoNurse and its utility in clinical settings. Usability Parameters: Quantitative and qualitative data were collected to evaluate the ChemoNurse mobile application’s usability. Quantitative data were obtained through the Mobile Application Usability Scale, which assessed key usability aspects, including visual design (color schemes, typography, font sizes), navigability, readability, responsiveness, and overall manageability. Descriptive statistical analyses were performed to summarize the responses to the 40-item, 7-point Likert-type scale, including frequency, mean, standard deviation, and percentage distributions. In addition to quantitative measures, open-ended items and structured feedback collected through the ChemoNurse Evaluation Form provided qualitative insights into the application’s usability. These included user perspectives on ease of use, clarity of information, integration into clinical workflows, and potential for continuous use. Responses to questions such as “Is the application easy to use?” and “Would you continue using the application in your daily practice?” were analyzed to support the interpretation of scale results. Ethical considerations This study was conducted in accordance with the principles outlined in the Declaration of Helsinki. Ethical approval was obtained from the Koç University Ethics Committee before the initiation of the study (Approval Number: 2022.216.IRB3.099, Date: 17.06.2022). Written informed consent was obtained from all participants before data collection. Participants were informed about the study’s purpose, procedures, potential risks and benefits, and their right to withdraw without any consequences. All data collected during the study were kept confidential and were anonymized before analysis. Results Descriptive characteristics of nurses The mean age of the nurses was 32.79 ± 6.55 years. It was found that 91.2% (n = 31) of the nurses were female, 38.2% (n = 13) had been working in the profession for more than 10 years, and 17.6% (n = 6) had been working in oncology units for more than 10 years. It was determined that 29.4% (n = 10) of the nurses worked in medical oncology units and 38.2% (n = 13) in pediatric hematology oncology clinics. In addition, 73.5% of the nurses worked as clinic nurses, and 20.6% (n = 7) had been practicing chemotherapy for more than 10 years. The characteristics of the nurses are presented in Table 3. Table 3Characteristics of the participantsVariablesn%GenderWoman3191.2Man38.8Patient group cared forChild1750.0Adult1750.0Duration of working in the nursing6–12 months38.81–5 years823.56–10 years1029.4Over 10 years1338.2Duration of working in oncology units6–12 months411.81–5 years1132.46–10 years1338.2Over 10 years617.6Working unitAdult chemotherapy unit514.7Pediatric hematology oncology clinic1338.2Pediatric bone marrow transplantation unit411.8Medical oncology clinic1029.4Management and education services25.9Position in the oncology clinicCharge nurse720.6Clinic nurse2573.5Case management nurse12.9Other12.9Duration of chemotherapy administrationLess than 1 year38.81–5 years1235.36–10 years1235.3Over 10 years720.6Mean+SDMin-MaxAge (min: 23, max:46)32.79 ± 6.5523–46SD: Standard deviation; Min: Minimum; Max: Maximum Characteristics of the participants SD: Standard deviation; Min: Minimum; Max: Maximum RE-AIM framework evaluation Reach The Reach dimension of the RE-AIM framework refers to the proportion and representativeness of individuals who participate in an intervention relative to the intended target population. In this study, participants were recruited through the Turkish Oncology Nursing Association, which has a membership base encompassing oncology nurse across multiple institutions and clinical settings throughout Turkey. Of the nurses invited to participate, 34 met the inclusion criteria and completed the evaluation, representing both pediatric (n = 17, 50%) and adult (n = 17, 50%) oncology settings across university hospitals, teaching hospitals, and other healthcare institutions. The sample included nurses with a broad range of professional experience, from less than one year to more than ten years. While the convenience sampling method and reliance on a single professional society limit the representativeness of this sample relative to the broader Turkish oncology nursing workforce, the inclusion of multiple institutional affiliations and clinical contexts provides a degree of diversity appropriate for a feasibility study. The demographic characteristics of participants are presented in Table 3. Perceived usefulness In this feasibility study, perceived usefulness was operationalized as nurses’ perceived impact of ChemoNurse on their clinical knowledge and practice, assessed via the ChemoNurse Evaluation Form after one week of application use. Within the RE-AIM framework, the “effectiveness” dimension conventionally refers to objective, measurable outcomes; however, in this feasibility context no such outcomes were assessed. Accordingly, this dimension is reframed here as “perceived usefulness” an exploratory implementation signal reflecting nurses’ self-reported perceptions of clinical relevance and practice alignment rather than any demonstrated clinical effect. Consistent with the exploratory scope of a feasibility study, no objective pre-post knowledge assessment was administered; therefore, the perceived usefulness data reported here reflects perceived rather than measured outcomes. Of the nurses, 91.2% reported that the application met their clinical needs, and 97.1% indicated they would continue using ChemoNurse, suggesting a strong perceived alignment between the application’s content and clinical practice requirements. These findings provide a preliminary signal that ChemoNurse may support nurses’ clinical decision-making; however, objective evaluation of improvements in knowledge, reductions in errors, or patient safety outcomes was beyond the scope of this feasibility phase. Future studies of perceived usefulness should incorporate validated pre- and post-test knowledge assessments and objective clinical performance measures to rigorously evaluate ChemoNurse’s impact on nursing competency and patient safety. Usability of ChemoNurse The results of the evaluation form for the usability of ChemoNurse are presented in Table 4 and 94.1% of the nurses stated that the application was easy, 100% said that the information in the application was understandable, 100% stated that it was suitable for clinical practice and 85.3% stated that the content of the drug guide in the application was sufficient. Table 4ChemoNurse usability testChemoNurse Usability TestYesNon%n%Is the ChemoNurse application easy?3294.125.9Is the information in the ChemoNurse application understandable?3410000Is ChemoNurse suitable for clinical practice?3410000Is the content of the ChemoNurse medication guide adequate?2985.3514.7Does the ChemoNurse application meet the clinical need?3191.238.8Is the ChemoNurse application cost-effective?3410000Would you use the ChemoNurse application continuously?3397.112.9n = 34; percentages are calculated based on the total sample ChemoNurse usability test n = 34; percentages are calculated based on the total sample Acceptability of ChemoNurse Based on the ChemoNurse Evaluation Form results, 91.2% of the nurses reported that the application met their clinical needs, 100% reported that they perceived the application as cost-effective, and 97.1% reported that they could use the ChemoNurse application continuously (Table 4). The mean satisfaction score was 7.11 ± 3.00 out of a possible 10, with a range of 1 to 10 and a median of 8. The distribution was positively skewed, with 42.9% of respondents assigning the highest possible score of 10. Overall, 61% of respondents (n = 21) rated their satisfaction between 7 and 10, reflecting strong approval (Fig. 3). However, 22.9% of participants (n = 8) rated their satisfaction at 4 or below, highlighting the importance of continuous iterative refinement to better address the needs of all users. Distribution of nurse satisfaction scores for the ChemoNurse mobile application Nurses’ qualitative responses further supported these findings. Regarding ease of use, one nurse stated: “The application is very practical; I can access drug information instantly without leaving the patient’s bedside.” Regarding clinical relevance, another noted: “Having preparation steps, side effects, and patient education all in one place is exactly what we need during a busy shift.” One nurse who rated her satisfaction lower commented: “The content is useful but some drug entries feel incomplete, particularly for less common agents.” These responses reflect both the strengths of the current version and the areas prioritized for further development. ChemoNurse The results of the ChemoNurse mobile application usability scale are presented in Table 4. The total Mobile Application Usability Scale score ranged from 140 to 280 (mean 246.76 ± 38.13; median 252.00, IQR: 228.00–271.00; 95% CI: 233.47–260.05), indicating a high level of perceived usability. No floor effects were observed; a ceiling effect was noted in a small number of participants who achieved the maximum possible score of 280, consistent with the high acceptability of the application within this sample. Subscale-level scores are presented in Table 5. Scores across all 40 items ranged from 5.53 ± 1.92 to 6.56 ± 0.60 on the seven-point scale. For descriptive purposes, 91.2% of participants (n = 31) scored above 200, representing scores exceeding 71% of the maximum possible score; this threshold was not derived from a validated cut-off and should be interpreted descriptively rather than as a formal criterion of favorable usability. No missing data were observed for any scale items, and no formal outlier exclusion was applied. Given that the maximum possible score on this scale is 280, the mean score obtained indicates that the application has a high level of usability. The fact that most participants scored 200 or higher also supports these results. In addition, the mean scores of the nurses for all questions in the Mobile Application Usability Scale were between 5.53 ± 1.92 and 6.56 ± 0.60, with a maximum of seven (Table 5). Table 5Mobile application usability Scale scores of usersScale itemsMean+SDMin-MaxThe mobile app uses beautiful visuals.6.56 ± 0.605–7Interesting, rich, beautiful and intriguing graphics were used in the mobile application.6.29 ± 1.032–7Effective/striking graphics were used in the mobile application.6.21 ± 1.222–7Beautiful and interesting graphics were used in the mobile application.6.12 ± 1.092–7Appropriate colors were used in the mobile application.6.50 ± 0.704–7Appropriate colors are used in the mobile application.6.50 ± 0.744–7There are very beautiful colors in the mobile application.6.44 ± 0.784–7Colors are not misused in the mobile application.6.21 ± 1.431–7In the mobile application, the main function of the application is made immediately visible/noticeable.6.44 ± 0.784–7The mobile app uses commands that are easy to understand/use.6.44 ± 0.893–7The mobile app uses clear/understandable controls.6.47 ± 0.784–7The controls used in the mobile app are easy to understand/use.6.47 ± 0.784–7The mobile application can be accessed in two different ways.5.91 ± 1.353–7The mobile application can be accessed through two different menus.5.82 ± 1.292–7The mobile app can be opened using one icon or menu.6.06 ± 1.073–7The mobile app is accessed using different icons or menu access points.6.12 ± 1.033–7Fingertip size controls were used in the mobile application.5.88 ± 1.451–7Fingertip size buttons were used in the mobile application.5.91 ± 1.421–7The mobile app uses oversized controls.6.29 ± 0.904–7The mobile app uses small controls that require you to select carefully before tapping.5.53 ± 1.921–7The mobile app makes use of a good typeface (font).6.35 ± 1.092–7The mobile app has a good font.6.38 ± 0.954–7The mobile app uses a good font size.6.35 ± 0.954–7The mobile app uses a font that I like.6.24 ± 1.281–7The mobile app uses similar shapes for similar components.6.00 ± 1.432–7Similar components are grouped together in the mobile app.6.18 ± 1.242–7Things that are connected (or belong to a whole) are grouped together in the mobile app.6.15 ± 1.182–7Similar shapes are used for similar components in the mobile app.5.91 ± 1.442–7The mobile app has a well-defined hierarchical structure.6.12 ± 1.291–7The mobile app uses a clear/understandable hierarchy.6.21 ± 1.271–7The mobile app uses headings to create a hierarchy on the screen.6.26 ± 1.053–7The mobile app uses headings to provide a hierarchy.6.35 ± 0.914–7Animations were used effectively to convey the content in the mobile application.6.06 ± 1.074–7Animations were used appropriately in the mobile application.6.09 ± 1.084–7Excessive/unnecessary animations were not used in the mobile application.5.71 ± 1.801–7The mobile app uses appropriate animations to convey content.5.91 ± 1.421–7The mobile app provides information when switching from one screen to another.5.79 ± 1.681–7The mobile app informs the user when to switch from one screen to another.5.94 ± 1.452–7The mobile app transitions smoothly from one screen to another.6.24 ± 1.202–7The mobile app transitions easily/smoothly from one screen to the next screen.6.35 ± 1.092–7Total Score246.76 ± 38.13142–280SD: Standard deviation; Min: Minimum; Max: Maximum; Total score range: 40–280 Mobile application usability Scale scores of users SD: Standard deviation; Min: Minimum; Max: Maximum; Total score range: 40–280 Efficiency of ChemoNurse Qualitative feedback from nurses regarding areas for improvement was subjected to thematic grouping, revealing four overarching clinical themes: (1) drug preparation and administration safety, (2) dosage accuracy and individualization, (3) clinical decision support and emergency preparedness, and (4) content organization and navigation. Theme 1. Drug Preparation and Administration Safety Nurses identified a need for more detailed guidance on subcutaneous drug preparation, specifically citing azacitidine (Vidaza) as an example. One nurse noted: “Preparation steps should explain that the drug must not contact the needle tip or skin, as this can cause skin toxicity.” They also indicated that drug stability and storage conditions were incomplete across several drug entries. These gaps are clinically significant: current ASCO/ONS Chemotherapy Administration Safety Standards explicitly require that nurses receive instruction on reconstitution techniques, safe handling, and storage conditions for antineoplastic agents to minimize occupational exposure and administration errors. The absence of such detail in the current version of ChemoNurse represents an alignment gap with established safety standards that warrants prioritization in future development. Theme 2. Dosage Accuracy and Individualization Multiple nurses highlighted that drug doses were not consistently presented in relation to diagnosis and body surface area (BSA), and that a BSA calculator was absent. One nurse stated, “Since drugs are dosed by m2, a BSA calculator should also be added.” Dose adjustment guidance for patients with renal or hepatic impairment was also identified as missing. These suggestions are consistent with ASCO clinical practice guidelines, which emphasize individualized dosing based on BSA and organ function as a core component of chemotherapy safety. The current version’s limitations in this domain may limit its utility for nurses managing complex patient profiles, and the integration of validated dosing calculators and organ-function-based adjustment guidance should be considered a high-priority development objective. Theme 3. Clinical Decision Support and Emergency Preparedness Nurses recommended that toxicities be grouped by chemotherapy protocol rather than individually, and that oncologic emergencies, including hypersensitivity and anaphylactic reactions, be incorporated. One nurse noted: “You can add oncologic emergencies such as hypersensitivity and allergic reactions.” Nurses also reported that minor side effects were absent for some drugs. According to the NCCN Clinical Practice Guidelines, the recognition and initial management of infusion-related hypersensitivity reactions are core competencies for all nurses administering chemotherapy. The absence of this content in ChemoNurse is a substantive clinical gap, particularly given that hypersensitivity events may require immediate intervention and that bedside nurses are often the first to identify early signs. Theme 4. Content Organization and Navigation Nurses suggested categorizing and alphabetizing drugs within their pharmacological class groups to facilitate faster retrieval. While this theme reflects usability rather than clinical content gaps, it is directly relevant to point-of-care efficiency. Evidence from mHealth usability literature supports that hierarchical and alphabetically organized drug databases significantly reduce search time in clinical settings, thereby potentially supporting more efficient drug administration workflows in future implementation contexts. These themes indicate that while ChemoNurse demonstrated high overall usability and acceptability, targeted content enhancements aligned with current international guidelines are needed before the application can be considered comprehensively fit for independent clinical decision support. These findings provide a clear developmental roadmap for the next version of ChemoNurse. Discussion This study was conducted to evaluate the feasibility, usability, and acceptability of the ChemoNurse mobile application, which was developed to support oncology nurses in the safe and effective administration of chemotherapy agents. Grounded in the ADDIE instructional design framework and shaped through a multidisciplinary development process, ChemoNurse was designed as a digital drug guide to provide structured, up-to-date information on chemotherapy drug preparation, routes of administration, dosing, symptom management, and patient education. The findings revealed that ChemoNurse was well received by its target users and demonstrated promising feasibility as a nurse-focused mHealth support tool. However, these findings should be interpreted within the scope of a feasibility study. This aligns with recent evidence indicating that digital tools tailored to nursing workflows may support the translation of knowledge and perceived clinical relevance in oncology settings; however, these potential benefits require confirmation through future perceived usefulness studies [31, 32]. The study results showed that 94.1% of participants found ChemoNurse easy to use, 100% stated the information was clear and understandable, and 85.3% reported that the drug guide content was sufficient for clinical use. These results indicate high levels of perceived usability and acceptability within this pilot sample. However, specific design features that influence usability (such as interface layout, navigation structure, or visual elements) were not directly evaluated in this study. Therefore, attributing high usability to specific design components is limited, and future studies are needed to examine this relationship in greater detail. Accordingly, the favorable usability findings should be interpreted as reflecting users’ overall perceptions of the application rather than the proven effect of any individual design element. Although the app includes features such as categorized drug grids, expandable symptom menus, and interactive viewers, the present study design does not allow causal conclusions regarding which features contributed most to usability outcomes. Prior studies underscore that digital health tools with clean layouts, responsive design, and minimized cognitive load enhance user experience and are associated with reduced perceived task burden, though evidence on actual error reduction remains limited [33, 34]. High usability is a foundational requirement for clinical adoption, particularly in oncology environments where time-critical decisions are frequent [21, 35]. It should be noted that prior studies on user experience in digital health were conducted in varied clinical settings, which limits their direct generalizability to the present context. The predominance of female participants (91.2%) is consistent with the nursing workforce’s demographic composition in Turkey, where nursing remains a female-dominated profession. This distribution therefore reflects the characteristics of the broader target population rather than a sampling artifact. Acceptability, a crucial factor in the success of digital interventions, was strongly supported by the participants. Specifically, 91.2% reported that the application met their clinical needs, 100% perceived it as cost-effective, and 97.1% indicated a willingness to continue using ChemoNurse in daily practice. The majority rated their satisfaction between 7 and 10 on a 10-point scale, reflecting strong approval of the app’s utility and relevance. These results suggest that nurses perceived ChemoNurse as a potentially supportive educational tool; however, actual integration into clinical workflows and its effects on practice were not directly assessed in this study. Prior studies have emphasized that user satisfaction is positively associated with factors such as clinical relevance, real-time accessibility, and alignment with professional responsibilities [36, 37]. Nurses are more likely to adopt digital tools that reduce ambiguity in drug administration, facilitate patient education, and reinforce evidence-based practice [22, 23]. Nevertheless, these findings are based on user perceptions and do not provide direct evidence that the application improves workflow efficiency, clinical competency, or quality of care. Such outcomes should be examined in future studies of perceived usefulness. It is important to note that the high satisfaction and usability ratings observed in this study should not be interpreted as an indication of clinical completeness. Qualitative feedback revealed several substantive content gaps, including incomplete information on drug stability and storage, absent dose adjustment guidance for patients with renal or hepatic impairment, missing oncologic emergency protocols, and the absence of a BSA-based dosing calculator. This discrepancy between overall satisfaction and identified content deficiencies likely reflects the fact that nurses evaluated the application’s usability and structural utility rather than its clinical comprehensiveness. These findings underscore that user satisfaction, while an important feasibility indicator, is insufficient as a standalone measure of clinical readiness, and that targeted content enhancements are required before ChemoNurse can be considered comprehensively fit for independent point-of-care decision support. The feasibility of ChemoNurse was further supported by scores on the Mobile Application Usability Scale, with 91.2% of nurses achieving a score above 200, and a mean total score of 246.76 ± 38.13 out of a possible 280. These findings indicate that the app demonstrated a high level of perceived usability during short-term real-world use. This is noteworthy, considering that the evaluation took place in high-pressure oncology settings where time efficiency and quick access to reliable information are essential. As highlighted by Skaczkowski et al. [31], the success of mHealth interventions in cancer care depends heavily on their seamless integration into the clinical environment, responsiveness, and scalability. In the present study, the modular structure of ChemoNurse and its rapid data retrieval performance during testing support its feasibility as a nurse-focused digital support tool. However, these findings should be interpreted as evidence of usability and early implementation potential rather than proof of clinical perceived usefulness. In this respect, the contribution of ChemoNurse may lie not only in its high usability ratings but also in its specific focus on chemotherapy-related nursing practice. A more focused comparison with related mobile health applications is also important. Compared with other health applications evaluated using the MAUS framework, the usability level observed for ChemoNurse appears favorable. For example, a 2025 study of a mobile application for urinary diary monitoring reported a mean MAUS score of 6.08 ± 1.25 among healthcare professionals, whereas the ChemoNurse total score of 246.76/280 corresponds to an item-average of approximately 6.17/7, suggesting a broadly comparable level of perceived usability [38]. At the same time, direct comparison across studies should be interpreted cautiously because applications differ substantially in target users, clinical purpose, evaluation context, and implementation period. In oncology specifically, some mobile applications have also shown favorable usability ratings, but many of these tools were designed for patients, symptom tracking, education, or self-management rather than for nurse-facing chemotherapy support, and some used different usability instruments, limiting strict score comparability. The high usability and satisfaction scores observed in this study should nonetheless be interpreted with caution given two methodological considerations. First, a ceiling effect was evident: a subset of participants achieved the maximum possible score of 280 on the Mobile Application Usability Scale, and 42.9% of respondents assigned the highest possible satisfaction score of 10, suggesting that the measurement instruments may not have been sufficiently sensitive to discriminate among highly favorable responses within this sample. This limits the precision with which the true distribution of user experience can be characterized and may inflate apparent mean scores. Second, voluntary recruitment through a single professional society is likely to have introduced selection bias toward nurses with higher digital literacy, stronger professional engagement, and greater openness to mHealth tools. Nurses who chose to participate after receiving an invitation through the Turkish Oncology Nursing Association may not be representative of the broader Turkish oncology nursing workforce, particularly those in less-resourced settings or with lower baseline technology familiarity. Together, these factors suggest that the usability and acceptability outcomes reported here may represent an optimistic estimate relative to what would be observed in a more heterogeneous or unselected population. Future studies employing probability-based sampling and more discriminating evaluation instruments are needed to obtain a less biased estimate of ChemoNurse’s usability across the full range of the intended user population. User feedback on perceived usefulness and development priorities highlighted several opportunities for improvement that further reinforce the importance of continuous app refinement. Nurses recommended incorporating more detailed subcutaneous drug administration instructions, adding a Body Surface Area (BSA) calculator, categorizing toxicities by chemotherapy protocols, and integrating emergency response guidance. These suggestions highlight the need for clinically nuanced content that extends beyond basic drug facts into practical, bedside decision-making support. Similar findings have been reported in studies that emphasize the added value of decision-support tools embedded in mHealth apps for guiding symptom triage, dose adjustments, and complication management [12, 39]. At the same time, these recommendations should be interpreted as user-identified development priorities rather than evidence that the current version of the application already improves clinical decision-making or patient safety. Future versions of ChemoNurse may benefit from such enhancements, but their effect should be tested using objective implementation and outcome measures. From a workflow perspective, ChemoNurse was designed to reduce the informational burden on oncology nurses by centralizing drug, symptom, and toxicity data within a single, rapidly accessible mobile platform. In high-acuity oncology environments, nurses frequently interrupt patient care to consult multiple reference sources, a practice that disrupts workflow, increases the task load, and poses a theorized risk of error, though direct evidence linking information fragmentation to chemotherapy errors in nursing practice is limited. Although the present study did not directly measure time savings or workflow efficiency, the high proportion of nurses reporting ease of use (94.1%) and clinical relevance (91.2%) suggests that ChemoNurse may have the structural prerequisites to support efficient point-of-care use in future implementation studies. The potential benefit may be particularly pronounced among novice nurses, for whom chemotherapy administration is widely recognized as one of the most anxiety-provoking clinical responsibilities. Accordingly, ChemoNurse should be positioned as a supplementary reference tool rather than a substitute for clinical judgment or interdisciplinary consultation, and future versions should incorporate content disclaimers prompting clinical verification to encourage critical engagement rather than passive reliance. A more direct comparison with related nursing and oncology mobile applications is also important. Much of the existing oncology mHealth literature has focused on patient-facing tools for symptom monitoring, self-management, education, or follow-up [40]. In contrast, ChemoNurse was developed specifically as a nurse-focused chemotherapy support application. Its content combines drug guidance with symptom-related information and patient education support across both adult and pediatric oncology contexts. This focus may address a more specific implementation gap in oncology nursing by targeting point-of-care informational needs during chemotherapy administration. Therefore, the findings of this study are broadly consistent with previous reports showing that clinically relevant digital tools can achieve high user acceptance, while also differing from much of the prior literature in terms of user group, clinical purpose, and workflow orientation. The content of the ChemoNurse app has been developed in line with both international chemotherapy safety standards and clinical practice requirements in Turkey. This suggests that certain aspects of the app may be specific to the local healthcare system context. However, the app’s fundamental structure, modular content organization, and evidence-based approach provide a framework that can be adapted to different healthcare systems. In this study, the duration of app use was limited to one week, which does not allow for a comprehensive evaluation of the adoption and maintenance dimensions within the RE-AIM framework. While short-term use reflects users’ initial experiences and perceptions of the application, it does not permit definitive conclusions about habit formation, long-term use behaviors, or integration into clinical workflows [22, 23]. Therefore, the long-term use and sustainability of the application should be evaluated in future studies. A critical dimension of ChemoNurse’s long-term clinical viability is its capacity to remain current with rapidly evolving chemotherapy protocols and safety standards. Information obsolescence poses a significant risk for clinical decision support tools, as outdated drug or dosing information can directly compromise patient safety. To address this, ChemoNurse incorporates a structured biannual content review process conducted by the multidisciplinary expert panel, with an expedited pathway for urgent safety updates. This process is modeled on best practices in clinical guideline maintenance and is consistent with recommendations from digital health governance frameworks, which emphasize that the credibility and safety of mHealth tools depend not only on their initial development quality but on the rigor and transparency of their ongoing content management. Future studies should evaluate whether this update mechanism is sufficient to maintain content currency in practice, and whether users’ awareness of version history influences their trust in and engagement with the application. Limitations This study has several limitations. First, the one-week usage period did not allow for assessment of long-term usage patterns, sustainable user engagement, or full integration into clinical workflows; longer follow-up studies are therefore needed. Second, self-reported measures were used to evaluate usability and perceived usefulness, which may be subject to response bias; moreover, the application’s design features, including interface structure and navigation, were not directly evaluated. Third, although nurses’ feedback was incorporated into the final design, real-time clinical implementation data, such as error reduction, patient outcomes, and nurse workload efficiency, were not captured, and validated objective outcome measures assessing clinical competency or direct improvements in nursing practice were absent. Fourth, the convenience sampling strategy and voluntary self-selection through a single professional society represent a significant source of selection bias. Nurses who actively engage with a professional organization, respond to digital recruitment invitations, and volunteer for technology evaluation studies are likely to differ systematically from the general oncology nursing population in terms of digital literacy, professional motivation, and openness to mHealth tools. This may have led to an overestimation of usability and acceptability outcomes, and the findings should therefore not be generalized to the broader oncology nursing workforce. Future studies should employ probability-based sampling across multiple institutions and professional networks to improve representativeness. Furthermore, although the sample was equally divided between pediatric and adult oncology nurses, no subgroup analyses were conducted to examine whether usability perceptions, acceptability ratings, or content feedback differed between these two groups. Given the substantial differences in chemotherapy protocols, dosing calculations, and clinical workflows across pediatric and adult oncology settings, this heterogeneity may have introduced undetected variability in the reported outcomes. The sample size of 17 nurses per subgroup was insufficient to support meaningful subgroup comparisons; future studies with larger samples should conduct such analyses to determine whether ChemoNurse requires context-specific adaptations for pediatric versus adult oncology nursing practice. Furthermore, the ChemoNurse Evaluation Form, developed through a structured content validation process and achieving a scale-level CVI of 0.92, employs a binary (Yes/No) response format that limits the granularity of feasibility and perceived impact assessments. Future studies should employ or develop instruments with ordinal or interval-level response options to enable more robust psychometric evaluation and nuanced interpretation of findings. Fifth, the study was conducted through a single professional society (the Turkish Oncology Nursing Association), drawing participants from multiple institutions across Turkey rather than from a single center; however, because the content was developed in accordance with local clinical requirements in Turkey, generalizability is limited. Chemotherapy protocols, antiemetic practices, and supportive care workflows vary across countries, institutions, and healthcare systems, which may further influence the intervention’s applicability in different contexts; adaptation may therefore be required before implementation elsewhere. As this platform represents an early-stage feasibility and usability model, the findings should be interpreted as preliminary, and caution is warranted when drawing conclusions regarding clinical performance, workflow efficiency, or patient safety. Larger multicenter studies with more diverse samples, longer-term follow-up, and stronger methodological designs incorporating objective performance metrics are needed to confirm the application’s broader applicability and scalability. Additionally, although the application’s clinical content was validated by a multidisciplinary expert panel prior to release, individual drug entries do not currently include embedded maximum-dose alerts or automated “red flag” warnings for dose thresholds. Given that chemotherapy dosing errors carry significant patient safety implications, integrating such safety features is a high-priority development objective for future versions of ChemoNurse. Until these features are implemented, the application should be used as a supplementary reference tool alongside institutional protocols and pharmacist verification, not as a standalone dosing authority. A further limitation concerns the clinical scope of ChemoNurse. The current version covers conventional cytotoxic chemotherapy agents only and does not include targeted therapies, immunotherapies, or combination regimens. Given the rapidly expanding use of these modalities in contemporary oncology practice and their substantially different toxicity profiles and monitoring requirements, this represents a meaningful gap in the application’s clinical coverage. Expanding the scope of ChemoNurse to encompass these treatment modalities is a priority objective for future development phases. Conclusion This study provides preliminary evidence that ChemoNurse, a mobile chemotherapy drug guide, demonstrates promising feasibility, usability, and acceptability among oncology nurses within this pilot sample. The positive usability and acceptability outcomes including high satisfaction scores, favorable feedback on clinical relevance, and a strong intention for continued use suggest that ChemoNurse addresses an important informational and practical support need in chemotherapy nursing practice. These findings indicate that digital tools of this nature have the perceived potential to support point-of-care access to chemotherapy information and to facilitate professional development among oncology nurses; whether these perceived benefits translate into measurable improvements in clinical practice or patient outcomes requires evaluation in future studies with objective outcome measures. The integration of oncology nurses’ feedback throughout the development process was a key strength of this study, ensuring that the application’s content and design were meaningfully aligned with the realities of clinical workflows. This participatory approach not only enhanced the tool’s practical relevance but also contributed to its high acceptability among end users. ChemoNurse, therefore, shows promise as a scalable digital support tool that is responsive to the informational demands of chemotherapy nursing. Nevertheless, several important caveats must be acknowledged when interpreting these findings. Because this study did not directly assess clinical performance, medication safety, knowledge acquisition, workflow efficiency, or patient outcomes, the results should not be interpreted as proof of clinical perceived usefulness. Any potential contribution of the application to nursing competency, patient safety, or the standardization of chemotherapy care should therefore be considered preliminary at this stage. Furthermore, the results were obtained from a convenience sample recruited through a single professional society, representing nurses from multiple institutions across Turkey but potentially over-representing those with higher professional engagement and digital literacy; this limiting the generalizability of the findings to other institutions and healthcare contexts. Future studies should address these limitations by evaluating ChemoNurse in diverse clinical settings with larger and more representative samples, longer follow-up periods, and validated objective measures of clinical competency, perceived usefulness, and, in later-phase trials, patient safety outcomes. The application’s adaptability to different healthcare systems, where chemotherapy protocols, antiemetic practices, and institutional workflows may vary considerably, also represents a critical area for future investigation. Multicenter trials incorporating stronger methodological designs are warranted to determine the application’s broader perceived usefulness, scalability, and implementation potential across varied oncology nursing contexts. Acknowledgements This work was presented as a proof poster at MASCC 2025 in Seattle. We would like to express our sincere gratitude to all oncology nurses, experts, and members of the advisory board who contributed to this study. Abbreviations Analysis, Design, Development, Implementation, Evaluation Body Mass Index Body Surface Area Mobile Chemotherapy Drug Guide for Oncology Nurses Confirmatory Factor Analysis Common Terminology Criteria for Adverse Events Programming language used with Flutter framework Firebase Cloud Messaging Global Cancer Observatory Hypertext Transfer Protocol Institutional Review Board JavaScript Object Notation Mobile Health Oncology clinical decision-support application Reach, Effectiveness, Adoption, Implementation, Maintenance User Interface User Experience World Health Organization Author contributions Conceptualization: RSS, AAK, FG, AT, ET, Eİ; Methodology: RSS, AAK, FG, AT, ET, LGK, BK, MEİ, ABY, ZK, BSG, EG; Application Development & Software Engineering: LGK, BK, MEİ, ABY, ZK, BSG, EG; Data Collection & Curation: Eİ, PY, EŞ, İYÇ; Formal Analysis & Investigation: RSS, AAK; Writing – Original Draft Preparation: RSS, EŞ, AAK, FG, AT, ET, BSG, EG; Writing – Review & Editing: RSS, FG, AT, AAK, Eİ, BSG, EG; Supervision: RSS, AAK, FG, AT, FSB, BSG, EG. Funding This project was funded by the Scientific and Technological Research Council of Türkiye (TÜBİTAK) under the 3501 – Career Development Program (CAREER), following a grant application submitted by the Oncology Nursing Association Research Commission Group and Koç University. Data availability Data are available upon reasonable request from the authors. Declarations Ethics approval and consent to participate This study was conducted following the principles outlined in the Declaration of Helsinki. Ethical approval was obtained from the Koç University Ethics Committee before the initiation of the study (Approval Number: 2022.216.IRB3.099, Date: 17.06.2022). Written informed consent was obtained from all participants before data collection. Participants were informed about the study’s purpose, procedures, potential risks and benefits, and their right to withdraw without any consequences. All data collected during the study were kept confidential and were anonymized before analysis. Consent for publication Not applicable. Authorship The authors declare that they meet the authorship criteria and agree on the content of this study Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Data are available upon reasonable request from the authors.